Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
Majid Khan, Aamir Aziz, Noah Shafi, et al.
Cells (2020) Vol. 9, Iss. 8, pp. 1869-1869
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
Arshad M. Khanani, Aamir Aziz, Hannah Khan, et al.
Eye (2023) Vol. 37, Iss. 17, pp. 3574-3581
Open Access | Times Cited: 88
Classification of diabetic retinopathy: Past, present and future
Zhengwei Yang, Tien‐En Tan, Yan Shao, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 86
Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
Paulo E. Stanga, F.J. Valentín-Bravo, Sebastian Stanga, et al.
Eye (2023) Vol. 37, Iss. 15, pp. 3282-3289
Open Access | Times Cited: 58
TENAYA and LUCERNE
Arshad M. Khanani, Aachal Kotecha, Andrew Chang, et al.
Ophthalmology (2024) Vol. 131, Iss. 8, pp. 914-926
Open Access | Times Cited: 51
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases
Massimo Nicolò, Lorenzo Ferro Desideri, Aldo Vagge, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 3, pp. 193-200
Closed Access | Times Cited: 97
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
Sławomir Liberski, Małgorzata Wichrowska, Jarosław Kocięcki
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9424-9424
Open Access | Times Cited: 68
The state of the art of bispecific antibodies for treating human malignancies
Shuhang Wang, Kun Chen, Qi Lei, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 9
Open Access | Times Cited: 65
Retinopathy of prematurity: A review of pathophysiology and signaling pathways
Mariza Fevereiro‐Martins, Carlos Marques‐Neves, Hercília Guimarães, et al.
Survey of Ophthalmology (2022) Vol. 68, Iss. 2, pp. 175-210
Open Access | Times Cited: 52
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema
Muhammad Z. Chauhan, Peyton A. Rather, Sajida M. Samarah, et al.
Cells (2022) Vol. 11, Iss. 12, pp. 1950-1950
Open Access | Times Cited: 51
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Lorenzo Ferro Desideri, Carlo Enrico Traverso, Massimo Nicolò, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1413-1413
Open Access | Times Cited: 38
Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Dalia T. Abdeldaim, Katharina Schindowski
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2402-2402
Open Access | Times Cited: 28
Assessment of Inner Blood–Retinal Barrier: Animal Models and Methods
Kiran Bora, Neetu Kushwah, Meenakshi Maurya, et al.
Cells (2023) Vol. 12, Iss. 20, pp. 2443-2443
Open Access | Times Cited: 25
Systemic Cytokines in Retinopathy of Prematurity
Po‐Yi Wu, Yuan-Kai Fu, Reyin Lien, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 291-291
Open Access | Times Cited: 23
Exercise alleviates neovascular age-related macular degeneration by inhibiting AIM2 inflammasome in myeloid cells
Bohao Cui, Xu Guo, Wei Zhou, et al.
Metabolism (2023) Vol. 144, pp. 155584-155584
Open Access | Times Cited: 23
Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
Anny M. S. Cheng, Sunir Joshi, Raphael Banoub, et al.
Cureus (2023)
Open Access | Times Cited: 22
Recent advances in bioaffinity strategies for preclinical and clinical drug discovery: Screening natural products, small molecules and antibodies
Haochun Jin, Dianxin Cui, Yu Fan, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103885-103885
Open Access | Times Cited: 7
Molecular and Cellular Mechanisms Involved in the Pathophysiology of Retinal Vascular Disease—Interplay Between Inflammation and Oxidative Stress
Jovana Srejovic, Maja Muric, Vladimir Jakovljević, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11850-11850
Open Access | Times Cited: 7
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
Prem N. Patel, Veeral Sheth
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2436-2436
Open Access | Times Cited: 40
LRG1 as a novel therapeutic target in eye disease
Giulia De Rossi, Marlene E. Da Vitoria Lobo, John Greenwood, et al.
Eye (2022) Vol. 36, Iss. 2, pp. 328-340
Open Access | Times Cited: 25
Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
Francesco Boscia, Daniele Veritti, Cristiana Iaculli, et al.
European Journal of Ophthalmology (2024) Vol. 34, Iss. 6, pp. 1675-1694
Closed Access | Times Cited: 5
Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration
Wissam Al-Jundi, Cristian Munteanu, Berthold Seitz, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2024) Vol. 262, Iss. 9, pp. 2867-2874
Closed Access | Times Cited: 5
Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials
Guoxian Li, Zhu Ning, Aimin Ji
Medicine (2023) Vol. 102, Iss. 50, pp. e36370-e36370
Open Access | Times Cited: 13
Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis
Dolly Ann Padovani-Claudio, Carla J. Ramos, Megan E. Capozzi, et al.
Progress in Retinal and Eye Research (2023) Vol. 94, pp. 101151-101151
Open Access | Times Cited: 12
Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy
Irini Chatziralli, Sara Touhami, Maria Vittoria Cicinelli, et al.
Eye (2021) Vol. 36, Iss. 4, pp. 692-703
Open Access | Times Cited: 27
In vitro and in vivo evaluation of electrospun poly (ε-caprolactone)/collagen scaffolds and Wharton's jelly mesenchymal stromal cells (hWJ-MSCs) constructs as potential alternative for skin tissue engineering
Liliana Lizarazo-Fonseca, Luz Correa-Araujo, Leonardo Prieto-Abello, et al.
Regenerative Therapy (2023) Vol. 24, pp. 11-24
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top